EarningsQ2 2026 Earnings Report
MX:EW Q2 2026 EPS Results
Actual EPS$13.26
Consensus EPS$12.63
Beat/MissBeat by +$0.63
One Year Ago EPS$11.39
MX:EW Q2 2026 Revenue Results
Actual Revenue$29.59B
Expected Revenue$28.90B
Beat/MissBeat by +$693.97M
YoY Revenue Growth+13.63%
Earnings Announcement Details
QuarterQ2 2026
Date07/23/2026
TimeAfter Close
Conference CallThursday, July 23, 2026
MX:EW Upcoming Earnings
Edwards Lifesciences's next earnings date is estimated for October 28, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:EW Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted robust top-line growth led by TMTT (+44.8% YoY) and solid TAVR performance (+10.5% YoY), along with margin expansion and upgraded full-year company and segment guidance. Notable clinical and regulatory milestones (SAPIEN X4S, PROGRESS timeline, PASCAL and M3 approvals/CE Mark, COMMENCE 10-year data) underpin multi-year growth prospects. Offsetting factors include foreign exchange headwinds, higher effective tax rate and GAAP earnings impacts from R&D credit changes, higher SG&A, and tougher second-half comparables creating near-term seasonality and uncertainty. On balance, positive execution, upgraded guidance and strong pipeline/clinical evidence outweigh the near-term financial and macro headwinds.Company Guidance
Strong Total Company Sales and Earnings
Q2 total sales of $1.74 billion, up 12.5% year-over-year; adjusted EPS of $0.78 (GAAP EPS $0.42). Company raised full-year 2026 sales guidance to 10%–11% (from 9%–11%) and reaffirmed full-year adjusted EPS guidance of $2.95–$3.05.
TAVR Growth and Leadership
TAVR Q2 sales of $1.3 billion, up 10.5% YoY. Growth driven by SAPIEN platform durability data, competitor exit benefit, stable ASPs, and similar growth in U.S. and OUS. Full-year TAVR sales guidance increased to 8%–9% (from 7%–9%); company reiterates mid- to high-single-digit long-term TAVR growth.
Rapid TMTT Expansion
TMTT (mitral & tricuspid) Q2 sales of $195.9 million, up 44.8% YoY. Broad-based adoption across PASCAL, EVOQUE and SAPIEN M3 exceeded expectations; TMTT guidance raised to $760M–$780M (from $740M–$780M) and company targets $2 billion in TMTT revenue by 2030.
Surgical Business Momentum and Durable Data
Surgical Q2 sales of $284 million, up 5% YoY. Favorable 10-year COMMENCE trial RESILIA durability data presented; U.S. approval received for ECLIPTIS surgical left atrial appendage device and planning major rollout.
Operating Profitability and Margin Expansion
Q2 adjusted operating profit margin of 30%; adjusted gross profit margin of 77.6% (flat YoY). Company expects full-year operating margin at the high end of original 28%–29% guidance and approximately 150 basis points of constant-currency operating margin expansion for the full year.
Product and Clinical Milestones
First patients treated with next-generation SAPIEN X4S; PROGRESS trial results slated for TCT; PARTNER 3 7-year SAPIEN durability data highlighted; next-generation PASCAL (Capture Clarity) and PASCAL tricuspid launches expected in Q4; CE Mark for SAPIEN M3 RESILIA obtained.
Strong Balance Sheet and Capital Allocation
Cash and cash equivalents of approximately $2.9 billion as of June 30, 2026; ~$1.5 billion remaining share repurchase authorization; average diluted shares ~578 million (guidance 575–580M).
Regional and Guideline Momentum
Outside-U.S. adoption supported by updated ESC/EACTS guidelines and Japan asymptomatic indication approval; CMS NCD reconsideration progressing with final policy expected in September—potential to expand Medicare beneficiary access.
MX:EW Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed